PharmaEngine
4162.TWO
2.25 USD
0.01
+0.45%
p
Overview
Last close
2.25 usd
Market cap
319.09M usd
52 week high
3.68 usd
52 week low
2.13 usd
Target price
3.81 usd
Valuation
P/E
6.1856
Forward P/E
N/A
Price/Sales
4.0099
Price/Book Value
2.1245
Enterprise Value
177.84M usd
EV/Revenue
2.2348
EV/EBITDA
2.6357
Key financials
Revenue TTM
79.58M usd
Gross Profit TTM
78.04M usd
EBITDA TTM
64.62M usd
Earnings per Share
0.37 usd
Dividend
0.19 usd
Total assets
161.02M usd
Net debt
N/A usd
About
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Symbol4162.TWO
- ExchangeTWO
- IsinTW0004162003
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Hong-Ren Wang Ph.D.
- HeadquarterTaipei
- Web sitehttps://www.pharmaengine.com
